Venetoclax, azacitidine, and G-CSF targeting molecular residual disease in CBFB::MYH11 AML resistant to high-dose cytarabine

Authors:

Abstract
Patients with acute myeloid leukemia (AML) with CBFB::MYH11 rearrangement who exhibit persistent measurable residual disease (MRD) or molecular relapse following high-dose cytarabine-based chemotherapy have a high risk to overt relapse. In this retrospective single center study, we evaluated the efficacy of the VAG regimen for MRD elimination in this setting. The regimen consisted of venetoclax (400 mg/day, days 1–21), azacitidine (75 mg/m²/day, days 1–7), and granulocyte colony-stimulating factor (5 μg/kg/day, days 1–7). Twenty-seven patients were included (20 with persistent MRD positivity, 7 with molecular relapse; median age, 39 years). Prior to VAG, 96.3% had received intensive chemotherapy (median, 5 cycles) and a median of 2 high-dose cytarabine cycles. The primary endpoint was molecular response, defined as a >0.5-log reduction or conversion to negativity in CBFB::MYH11 transcript levels. After one VAG cycle, median transcript levels declined significantly from 0.120% to 0.0275% (P = 0.0018), representing a median 0.6-log reduction. Among the 26 evaluable patients, 18 (69.2%) achieved an MRD response following VAG treatment after 1–3 cycles of VAG. Median event-free survival and overall survival were not reached. These findings suggest that the VAG regimen represents a clinically meaningful strategy for MRD clearance in CBFB::MYH11-positive AML refractory to HDAC-based consolidation therapy.